Lilly is upping its bet on Alzheimer’s. The Indianapolis-based drug maker announced it has licensed experimental tracers that can hone in on and mark tau tangles that are believed to be a cause of...
For many docs, ambivalence about taking gifts starts early
Apr 02, 2013
The stereotypical law student’s first day is summed up as follows: Students think they are entering the field for the public good while their neighbors are in it for a hefty paycheck. A study published...
Failures halt Phase III trials of infused Alzheimer’s drug
Sep 01, 2012
Pfizer, Johnson & Johnson, and Elan said all Phase III tests of Alzheimer’s drug bapineuzumab are being halted after the drug failed to hit its goals for cognition and global function.
Analyst seeks split-up for drugmaker J&J
Jul 05, 2012
Goldman Sachs analyst Jami Rubin’s dream of a Johnson & Johnson break-up will not be deterred. In what amounts to a 23-page wish list, the analyst laid out reasons for breaking up the company in...
Dementia drug dosage comes under fire
May 01, 2012
The Food and Drug Administration “breached its own regulatory standard” when it permitted a new dosage for a best-selling Alzheimer’s drug, according to two professors at Dartmouth’s...